Imaging Endpoints — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$255	3
2023	Research	$595	7
2022	Research	$17,512	12
2021	Research	$59,506	45
2020	Research	$49,081	13

Breakdown

Who paid Research payments · program years 2020–2024

Amgen Inc. $70,140 6 payments
EMD Serono, Inc. $54,084 36 payments
Sun Pharmaceutical Industries Inc. $1,874 28 payments
Ares Trading SA $850 10 payments

Studies the money was for Research payments · program years 2020–2024

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety. $54,084 36 payments
Phase 2b SLE Dose-Finding $28,901 2 payments
Phase 2b - SLE Dose-Finding $24,392 2 payments
P2b SLE Dose-Finding $16,847 2 payments
Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) $1,209 18 payments
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) $665 10 payments
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety. $595 7 payments
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety. $255 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.